IL21 and acute myeloid leukemia: As an increasing number of selective drug delivery and targeted immunotherapy strategies are being currently developed and optimized, a potential exists for translating IL-21 into clinical application, for example by combination with standard-of-care treatment regimens as demonstrated in our study or by mean of bi- or tri-specific antibodies or chimeric antigen receptor (CAR) T cells that target AML LSCs.